L'âge est-il un facteur de risque pour les anomalies des 5' UTR ?
Oui, l'âge avancé peut augmenter le risque de mutations dans les 5' UTR et d'autres gènes.
ÂgeMutations
#3
Les habitudes alimentaires influencent-elles les 5' UTR ?
Certaines habitudes alimentaires peuvent affecter l'expression des gènes, y compris les 5' UTR.
Habitudes alimentairesExpression des gènes
#4
Le stress peut-il affecter les 5' UTR ?
Oui, le stress peut influencer l'expression génique et potentiellement affecter les 5' UTR.
StressExpression génique
#5
Les infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?
Certaines infections virales peuvent induire des modifications dans les 5' UTR, augmentant les risques.
Infections viralesModifications génétiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions 5' non traduites : Questions médicales les plus fréquentes",
"headline": "Régions 5' non traduites : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions 5' non traduites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions 5' non traduites"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Régions non traduites",
"url": "https://questionsmedicales.fr/mesh/D020506",
"about": {
"@type": "MedicalCondition",
"name": "Régions non traduites",
"code": {
"@type": "MedicalCode",
"code": "D020506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions 5' non traduites",
"alternateName": "5' Untranslated Regions",
"code": {
"@type": "MedicalCode",
"code": "D020121",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nicola Whiffin",
"url": "https://questionsmedicales.fr/author/Nicola%20Whiffin",
"affiliation": {
"@type": "Organization",
"name": "National Heart and Lung Institute and MRC London Institute of Medical Science, Imperial College London, London W12 0NN, UK."
}
},
{
"@type": "Person",
"name": "Olga A Nikolaitchik",
"url": "https://questionsmedicales.fr/author/Olga%20A%20Nikolaitchik",
"affiliation": {
"@type": "Organization",
"name": "Viral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Vinay K Pathak",
"url": "https://questionsmedicales.fr/author/Vinay%20K%20Pathak",
"affiliation": {
"@type": "Organization",
"name": "Viral Mutation Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Wei-Shau Hu",
"url": "https://questionsmedicales.fr/author/Wei-Shau%20Hu",
"affiliation": {
"@type": "Organization",
"name": "Viral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA."
}
},
{
"@type": "Person",
"name": "William E Tapprich",
"url": "https://questionsmedicales.fr/author/William%20E%20Tapprich",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, University of Nebraska at Omaha, Omaha, Nebraska, USA wtapprich@unomaha.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36546488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4102/phcfm.v14i1.3736"
}
},
{
"@type": "ScholarlyArticle",
"name": "Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37850783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.23750/abm.v94i5.13751"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.",
"datePublished": "2022-08-12",
"url": "https://questionsmedicales.fr/article/35964881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvir.2022.08.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate organogenesis.",
"datePublished": "2022-06-21",
"url": "https://questionsmedicales.fr/article/35726824",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1242/dev.200394"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36974872",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i3.4613"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Régions non traduites",
"item": "https://questionsmedicales.fr/mesh/D020506"
},
{
"@type": "ListItem",
"position": 9,
"name": "Régions 5' non traduites",
"item": "https://questionsmedicales.fr/mesh/D020121"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions 5' non traduites - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions 5' non traduites",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions 5' non traduites",
"description": "Comment identifier les 5' UTR dans un gène ?\nQuels tests sont utilisés pour étudier les 5' UTR ?\nLes 5' UTR sont-elles visibles sur des électrophorèses ?\nPeut-on détecter des mutations dans les 5' UTR ?\nQuel rôle jouent les 5' UTR dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Prostate#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions 5' non traduites",
"description": "Les 5' UTR sont-elles liées à des symptômes cliniques ?\nQuels symptômes peuvent indiquer un problème avec les 5' UTR ?\nLes 5' UTR affectent-elles la réponse aux traitements ?\nPeut-on relier les 5' UTR à des syndromes spécifiques ?\nLes 5' UTR sont-elles impliquées dans des cancers ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Prostate#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions 5' non traduites",
"description": "Peut-on prévenir les anomalies des 5' UTR ?\nY a-t-il des facteurs environnementaux affectant les 5' UTR ?\nComment le mode de vie influence-t-il les 5' UTR ?\nLes dépistages génétiques aident-ils à prévenir les problèmes liés aux 5' UTR ?\nLes vaccinations influencent-elles les 5' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Prostate#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions 5' non traduites",
"description": "Comment les traitements ciblent-ils les 5' UTR ?\nLes médicaments peuvent-ils interagir avec les 5' UTR ?\nY a-t-il des traitements pour corriger les anomalies des 5' UTR ?\nLes traitements ciblant les 5' UTR sont-ils efficaces ?\nLes 5' UTR influencent-elles la résistance aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Prostate#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions 5' non traduites",
"description": "Quelles complications peuvent survenir avec des anomalies des 5' UTR ?\nLes anomalies des 5' UTR peuvent-elles entraîner des complications héréditaires ?\nComment les 5' UTR affectent-elles le pronostic des maladies ?\nLes complications liées aux 5' UTR sont-elles réversibles ?\nLes 5' UTR sont-elles impliquées dans des complications post-thérapeutiques ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Prostate#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions 5' non traduites",
"description": "Quels sont les facteurs de risque pour les anomalies des 5' UTR ?\nL'âge est-il un facteur de risque pour les anomalies des 5' UTR ?\nLes habitudes alimentaires influencent-elles les 5' UTR ?\nLe stress peut-il affecter les 5' UTR ?\nLes infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Prostate#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les 5' UTR dans un gène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les 5' UTR peuvent être identifiées par séquençage d'ARN et analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les 5' UTR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le RT-PCR et les analyses de l'expression génique."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles visibles sur des électrophorèses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être visualisées sur des gels d'électrophorèse après amplification."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les 5' UTR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être détectées par séquençage ciblé des régions 5' UTR."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les 5' UTR dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles influencent la régulation de l'expression génique, affectant le diagnostic de maladies."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles liées à des symptômes cliniques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans les 5' UTR peuvent entraîner des symptômes variés selon le gène affecté."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les 5' UTR ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des troubles métaboliques ou des maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Les 5' UTR affectent-elles la réponse aux traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations dans les 5' UTR peuvent influencer l'efficacité des traitements médicamenteux."
}
},
{
"@type": "Question",
"name": "Peut-on relier les 5' UTR à des syndromes spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations dans les 5' UTR sont associées à des syndromes génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles impliquées dans des cancers ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations dans les 5' UTR peuvent contribuer à la carcinogenèse dans certains cancers."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des 5' UTR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des conseils génétiques et un suivi médical pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux affectant les 5' UTR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des gènes liés aux 5' UTR."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il les 5' UTR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque d'anomalies génétiques, y compris celles des 5' UTR."
}
},
{
"@type": "Question",
"name": "Les dépistages génétiques aident-ils à prévenir les problèmes liés aux 5' UTR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage génétique peut identifier les risques et permettre une intervention précoce."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles les 5' UTR ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations n'affectent pas directement les 5' UTR, mais protègent contre certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment les traitements ciblent-ils les 5' UTR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des oligonucléotides peuvent cibler les 5' UTR pour moduler l'expression."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils interagir avec les 5' UTR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent moduler l'activité des 5' UTR, influençant la traduction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements pour corriger les anomalies des 5' UTR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de thérapie génique sont en développement pour corriger ces anomalies."
}
},
{
"@type": "Question",
"name": "Les traitements ciblant les 5' UTR sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité dépend du type de mutation et du contexte biologique de la maladie."
}
},
{
"@type": "Question",
"name": "Les 5' UTR influencent-elles la résistance aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations dans les 5' UTR peuvent être liées à la résistance aux traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des 5' UTR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des maladies métaboliques, des cancers ou des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les anomalies des 5' UTR peuvent-elles entraîner des complications héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent être transmises et causer des complications héréditaires."
}
},
{
"@type": "Question",
"name": "Comment les 5' UTR affectent-elles le pronostic des maladies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les variations dans les 5' UTR peuvent influencer le pronostic et la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Les complications liées aux 5' UTR sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la maladie."
}
},
{
"@type": "Question",
"name": "Les 5' UTR sont-elles impliquées dans des complications post-thérapeutiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des modifications dans les 5' UTR peuvent contribuer à des complications après traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des 5' UTR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et des mutations."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les anomalies des 5' UTR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations dans les 5' UTR et d'autres gènes."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles les 5' UTR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires peuvent affecter l'expression des gènes, y compris les 5' UTR."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter les 5' UTR ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut influencer l'expression génique et potentiellement affecter les 5' UTR."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent induire des modifications dans les 5' UTR, augmentant les risques."
}
}
]
}
]
}
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, P.R. China.
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, P.R. China.
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, P.R. China.
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, P.R. China.
Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA; School of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195, USA. Electronic address: ahsieh@fredhutch.org.
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...
To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla...
A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a...
Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24...
PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...
Prostate organogenesis begins during embryonic development and continues through puberty when the prostate becomes an important exocrine gland of the male reproductive system. The specification and gr...
Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le...
This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ...
A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu...
BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...
Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin...
A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch...
Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ...
Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...
The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV)....
The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr...
In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/...
Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...
Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...
This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population....
A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an...
140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand...
The PHI test improves PCa detection compared to tPSA in our population....
We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy....
This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf...
A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta...
Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...
